(Q41579468)

4 October 2017

1 reference

title

The assessment of treatment outcomes in metastatic prostate cancer: changing endpoints (English)

1 reference

4 October 2017

Dawson NA

1

1 reference

PubMed ID

9274435

4 October 2017

McLeod DG

series ordinal

2

1 reference

4 October 2017

1 April 1997

1 reference

European Journal of Cancer

4 October 2017

1 reference

4 October 2017

33

1 reference

4 October 2017

4

1 reference

4 October 2017

560-565

1 reference

STUDIES ON PROSTATIC CANCER

4 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Do bone scans predict prognosis in prostatic cancer? A report of the EORTC protocol 30762

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Nuclear bone imaging in metastatic cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

The flare phenomenon on radionuclide bone scan in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Quantitative bone scanning: a method for assessing response of bone metastases to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Computerized bone scan. A potentially useful technique to measure response in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

The importance of prognostic factors in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Serial bone scanning: the assessment of treatment response in carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

The usefulness of prostate-specific antigen and prostatic acid phosphatase in clinical practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Biochemical monitoring of carcinoma of prostate treated with an LH-RH analogue (Zoladex)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

The CARES: a generic measure of health-related quality of life for patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Measuring the quality of life of cancer patients: a concise QL-index for use by physicians.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

The MOS short-form general health survey. Reliability and validity in a patient population

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Evaluation of quality of life in patients receiving treatment for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900443-1

7 January 2021

10.1016/S0959-8049(96)00443-1

Identifiers

DOI

1 reference

4 October 2017

1 reference

PubMed ID

9274435